ARGX
861.727 EUR
-3.12%
Today
-4.48%
1D
Market is closed
Sun
Closed
Mon
10:01 AM ~ 6:30 PM
Tue
10:01 AM ~ 6:30 PM
Wed
10:01 AM ~ 6:30 PM
Thu
10:01 AM ~ 6:30 PM
Fri
10:01 AM ~ 6:30 PM
Sat
Closed
Information
Name
Argenx Leveraged ( BE )
Currency
EUR
Standard Leverage
1X
Enhanced Leverage
3X
Overnight Fees Buy
-0.0144%
Overnight Fees Sell
-0.0023%
Market Cap
53.74B
Avg Daily Volume
95.38K
52 Week High
903 EUR
52 Week Low
568.4 EUR
Trading Hours
See hours
Overnight Fees Calculator
| Daily Overnight Fee % | Daily Overnight Fee $ | |
|---|---|---|
| BUYS | -0.01440% | $(0.144) |
| SELLS | -0.00230% | $(0.023) |
*Results displayed are estimates. Actual fees may differ from those shown as market conditions change.
Business Summary
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Top News
Argenx
-4.48%
Nokia
+0.60%
BancoSantander
-13.46%
WPP_PLC
+5.34%
European Equities Traded in the US as American Depositary Receipts Track Slightly Lower in Monday Trading
finance.yahoo.com
14h ago
Argenx
-4.48%
Corcept
+1.97%
Biotech Stocks At 52-Week Highs - ELOX, PRLD, ARGX, BOLD, CORT
tradingview.com
18h ago
Argenx
-4.48%
Weekly Recap: VYVGART Phase 3 win and ARGX price targets raised
tradingview.com
1d ago
Show more
Frequently Asked Questions
What are healthcare stocks and why are they important to investors?
Healthcare stocks include pharmaceutical companies, biotech firms, hospitals, and medical device manufacturers.
Are healthcare stocks less volatile?
Generally yes. Because healthcare is a necessity, demand remains relatively steady, making the sector less sensitive to economic cycles.
What drives growth in healthcare investments?
Aging populations, technological advancements, and increased healthcare spending contribute to long-term growth in the sector.
What are the risks of investing in healthcare?
Regulatory changes, drug approval delays, and legal challenges can affect the profitability and stock prices of healthcare companies.
